OMass Therapeutics

OMass Therapeutics is a biotechnology company based in Oxford, UK, and was established as a spin-out from Oxford University. Originally founded as OMass Technologies in 2016, it rebranded in 2018 to concentrate on developing its own therapeutics. The company is known for its innovative drug discovery approach, utilizing its proprietary OdyssION™ technology platform. This platform integrates advanced biochemistry techniques and next-generation mass spectrometry to explore target molecules and their interactions in their natural environments. The company specializes in discovering medicines for validated target ecosystems, including membrane proteins and GPCRs. OMass Therapeutics aims to develop small molecule therapeutics for rare diseases and immunological conditions. It has garnered significant attention and investment from major pharmaceutical and biotechnology firms, reflecting confidence in its technology and potential. With over $160 million raised from a diverse group of investors, OMass Therapeutics has been recognized as a promising player in the biotech industry, including being named a "Fierce 15" winner by Fierce Biotech in 2024.